Drugmaker Novartis filed suit to block Maryland's recently signed 340B contract pharmacy statute.

Novartis to Refund Covered Entities After Adjusting 340B Ceiling Prices for 100-Plus Products

Thousands of covered entities that purchased more than one hundred Novartis products between late 2019 and early 2023 will be [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.